Last reviewed · How we verify

NCT03386136: TOGA

Therapeutic Oxygen for Gastrointestinal Atony (TOGA)

Completed Phase 1 Last updated 12 December 2019
What this trial tests

Phase 1 trial testing 100% Oxygen in Ileus in 17 participants. Completed in 17 October 2019.

Timeline
25 January 2018
Primary endpoint
17 October 2019
17 October 2019

Quick facts

Lead sponsorUniversity of Florida
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment17
Start date25 January 2018
Primary completion17 October 2019
Estimated completion17 October 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Florida

Who can join

Adults 18 to 100, any sex, with Ileus or Ogilvie Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a non invasive study to see if 100% oxygen therapy will help to resolve an intestinal obstruction.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. TOGA Therapeutic Oxygen for Gastrointestinal Atony.
    Weiner B, Forsmark C, Khular V, Bauman A, et al · · 2024 · cited 2× · PMID 39131150 · DOI 10.1016/j.gastha.2023.12.013

Verify or expand the search:

Other trials of 100% Oxygen

Trials testing the same drug.

Other recruiting trials for Ileus

Currently open trials in the same condition.

Other University of Florida trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03386136.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing